Political and business events presage change for stem cell therapeutics, most notably the expected move by President Barack Obama to lift federal funding restrictions on stem-cell research. The U.S. Congress has also indicated a desire to move forward with stem cell research. The momentum in two branches of American government, along with scientific developments and the competition of world markets presages good market conditions for stem cell research.
With their ability to differentiate and become an ongoing source of cells that make up critical tissues and organs, stem cells have potential for new regenerative therapies and as new research tools for drug developers to test emerging therapies on diseased cells.
While companies have found opportunity outside the U.S., President Bush's seven year limitations on embryonic stem cell research in the U.S. has limited the U.S. market. Changes in U.S. policy should open up U.S. markets. For market-watchers in the pharmaceutical industry, the question is what potential they have and where they could take the market. Kalorama Information has tackled that question in Stem Cells Therapeutics Markets. Kalorama analyst Alison Sahoo has built models to determine the best case and most likely case scenarios for therapeutic markets for stem cells in the coming years.
This report breaks down forecasted revenues and procedure volumes for stem cell technologies for these segments in the following disease areas:
- Cardiovascular disease
- Lung disease
- Arthritis
- Incontinence
- Osteoporosis
- Diabetes
- Cancer
- Orthopedics
- Infertility
- Alzheimer’s disease
- Burns (severe)
- Lupus
- Parkinson’s disease
- Liver failure
- Multiple sclerosis
- Critical limb ischemia
- Crohn's disease
- Sickle cell disease
- Multiple myeloma
- NH lymphoma
- Leukemia
Ths report is the result of exclusive interviews with executives in the stem cell industry, a review of medical and company literature, government databases and publications. As part of this comprehensive analysis of stem cell markets, the following companies were profiled:
- Aastrom Biosciences
- Advanced Cell Technologies
- Brainstorm Cell Therapeutics
- Celegene
- ES Cell International
- Medistem
- Neostem
- Opexa Therapeutics
- Osiris Therapeutics
- Plureon
- Regenetech
- Revivicor
- Stem Cell Sciences
- StemLifeLine
- ThermoGenesis
- VetCell Bioscience